Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2023

06-02-2023 | Cytostatic Therapy | Peritoneal Surface Malignancy

Evaluating End Points of the Efficacy of Intraperitoneal Chemotherapy Techniques Including PIPAC

Authors: Kevin M. Sullivan, MD, Mustafa Raoof, MD

Published in: Annals of Surgical Oncology | Issue 5/2023

Login to get access

Excerpt

Peritoneal metastases (PM) are challenging to treat, with progressive disease resulting in significant detriments to both quality of life and survival for patients. Currently, two accepted treatment methods for PM are available: systemic chemotherapy and cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC). For patients who are not candidates to receive CRS with or without HIPEC, pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a novel method for delivering repeatable intraperitoneal (IP) chemotherapy as a minimally invasive laparoscopic procedure. …
Literature
1.
2.
Tempfer CB, Winnekendonk G, Solass W, Horvat R, Giger-Pabst U, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study. Gynecol Oncol. 2015;137:223–8.CrossRefPubMed
3.
Struller F, Horvath P, Solass W, Weinreich FJ, Strumberg D, Kokkalis MK, et al. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study. Ther Adv Med Oncol. 2019;11:1758835919846402.CrossRefPubMedPubMedCentral
4.
Khomyakov V, Ryabov A, Ivanov A, Bolotina L, Utkina A, Volchenko N, et al. Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and doxorubicin administered as a pressurized aerosol: an open-label, phase-2 study (PIPAC-GA2). Pleura Peritoneum. 2016;1:159–66.CrossRefPubMedPubMedCentral
5.
Graversen M, Detlefsen S, Bjerregaard JK, Fristrup CW, Pfeiffer P, Mortensen MB, et al. Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. Ther Adv Med Oncol. 2018;10:1758835918777036.CrossRefPubMedPubMedCentral
6.
Dumont F, Passot C, Raoul JL, Kepenekian V, Lelièvre B, Boisdron-Celle M, et al. A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers. Eur J Cancer. 2020;140:37–44.CrossRefPubMed
7.
Kim G, Tan HL, Sundar R, Lieske B, Chee CE, Ho J, et al. PIPAC-OX: a phase I study of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy in patients with peritoneal metastases. Clin Cancer Res. 2021;27:1875–81.CrossRefPubMed
8.
Rovers KP, Wassenaar EC, Lurvink RJ, Creemers GJ, Burger JW, Los M, et al. Pressurized Intraperitoneal aerosol chemotherapy (oxaliplatin) for unresectable colorectal peritoneal metastases: a multicenter, single-arm, phase II trial (CRC-PIPAC). Ann Surg Oncol. 2021;28:5311–26.CrossRefPubMed
9.
Robella M, De Simone M, Berchialla P, Argenziano M, Borsano A, Ansari S, et al. A phase I dose escalation study of oxaliplatin, cisplatin, and doxorubicin applied as PIPAC in patients with peritoneal carcinomatosis. Cancers Basel. 2021;13:1060.CrossRefPubMedPubMedCentral
Metadata
Title
Evaluating End Points of the Efficacy of Intraperitoneal Chemotherapy Techniques Including PIPAC
Authors
Kevin M. Sullivan, MD
Mustafa Raoof, MD
Publication date
06-02-2023
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 5/2023
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-023-13124-z

Other articles of this Issue 5/2023

Annals of Surgical Oncology 5/2023 Go to the issue

Pancreatic Tumors

Race, Insurance, and Sex-Based Disparities in Access to High-Volume Centers for Pancreatectomy

Translational Research

Prognostic Significance of the Histopathological Growth Pattern and Tumor-Infiltrating Lymphocytes in Stratifying Survival After Hepatectomy for Colorectal Liver Metastases

Aso Visual Abstract

ASO Visual Abstract: Epidemiologic Survey of Myxofibrosarcoma Using Data from the Bone and Soft Tissue Tumor Registry in Japan

ASO Visual Abstract

ASO Visual Abstract: The Current State of Liver Transplantation for Colorectal Liver Metastases in the United States: A Call for Standardized Reporting

ASO Author Reflections

ASO Author Reflections: Surgical Strategy for Bilobar Colorectal Liver Metastases with Vascular Invasion

ASO Author Reflections

ASO Author Reflections: Role of the Computed Tomography Maximum in Pancreatic Neuroendocrine Tumors